Home Events CPHI South East Asia: Pharmacogenomics – Drugs That Kill

CPHI South East Asia 2025 Panel Recap: Pharmacogenomics - Drugs That Kill?

Pictures taken during the panel session involving Dr Rebecca (in the center), in between of Dr Ngu and Prof Dr Teh, moderated by Mr Ahmad Fazil bin Elias (on the left)

Panel Discussion at the CPHI South East Asia 2025

Precision Diagnostics is proud to share that our CEO, Dr. Rebecca Tay Sook Hui, to participate and partake in a timely and thought-provoking panel discussion at CPHI South East Asia 2025, titled “Pharmacogenomics: Drugs That Kill?’.

It was also an honour for Dr. Rebecca to speak alongside;

Prof. Dr. Teh Lay Kek, Faculty of Pharmacy, UiTM Puncak Alam
Dr. Ngui Lock Hock, Head of Genetics, Hospital Kuala Lumpur

including the moderator, Mr. Ahmad Fazil bin Elias, Assistant Vice President of the Malaysian Bioeconomy Development Corporation. Our sincere thanks to Informa Markets and Bioeconomy Corporation for organizing this important platform to discuss on the revelation of personalized medicine for the future.

Reflections from the Session

Pharmacogenomics is steadily gaining ground as a valuable tool in optimising drug therapy and reducing adverse drug reactions. However, several key challenges remain:

Limited practitioner exposure to genetic testing
Gaps in access to actionable patient-level data
Integration difficulties with clinical workflows and EMRs

During the session, PRECISE Pharmacogenomics was highlighted as Malaysia’s first clinically recommended genome-wide pharmacogenomics for drug-gene interactions. Developed based on internationally recognised guidelines, PRECISE is designed to support doctors in making more informed prescribing decisions across multiple therapeutic areas.

We remain committed to working alongside clinicians, researchers, and healthcare leaders to expand access to personalised diagnostics that are evidence-informed, clinically relevant, and suited for the needs of the Malaysian healthcare landscape.

About Convention on Pharmaceutical Ingredients (CPHI)

The Convention on Pharmaceutical Ingredients (CPHI) is a leading global pharmaceutical industry event that brings together professionals, innovators, and organisations from across the pharmaceutical supply chain. It serves as a key platform for networking, knowledge exchange, partnerships, and exploring the latest developments in pharmaceutical ingredients, manufacturing, technology, and healthcare innovation.

About Precision Diagnostics

Precision Diagnostics is a precision medicine and genomic diagnostics organisation committed to translating advances in genomics into clinically meaningful healthcare solutions supported by clinical governance. Through its work in pharmacogenomics, precision oncology, genomic testing, clinical implementation, and international scientific collaboration, Precision Diagnostics aims to support safer, more personalised, and evidence-based patient care across Malaysia and the Asia-Pacific region.